Labcorp Holdings (LH) news from Bullished: SEC filings, earnings, insider trades and deals, explained in plain English with links to the source documents.
Earnings
A Baird analyst said he could not reproduce year-one accretion from the BioReference deal, and CEO Adam Schechter answered with history, not numbers.
Earnings
The CFO sized the 2027 hit while the CEO said proposed rates draw on data from only 2% of laboratories, and the long-term outlook stands.
Markets
Labcorp now expects $18.30 to $18.70 in adjusted earnings per share for the year, while its CEO flagged a $125 million Medicare fee-cut hit.
Earnings
Revenue rose 6.9% to $3.81 billion, and the lab company announced or closed four deals while lifting its full-year forecast.